Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.73Aarey Drugs & Pharmaceuticals Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and profitability, indicating a solid financial foundation and efficient operations. However, growth metrics present a challenge, with declines in operating profit, EPS, asset growth, and net income. Liquidity is adequate, but there's room for improvement in managing short-term obligations. While the company shows good asset turnover and inventory management, collection periods for receivables are lengthy, impacting cash flow. Overall, Aarey Drugs & Pharmaceuticals showcases resilience but needs to address growth concerns to ensure long-term sustainability and competitiveness.
Health Score : 5.73Aarey Drugs & Pharmaceuticals Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and profitability, indicating a solid financial foundation and efficient operations. However, growth metrics present a challenge, with declines in operating profit, EPS, asset growth, and net income. Liquidity is adequate, but there's room for improvement in managing short-term obligations. While the company shows good asset turnover and inventory management, collection periods for receivables are lengthy, impacting cash flow. Overall, Aarey Drugs & Pharmaceuticals showcases resilience but needs to address growth concerns to ensure long-term sustainability and competitiveness.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
60.35
Industry Median
30.38
Small Cap Median
28.83
P/E RATIO
60.35
P/B RATIO
1.59
Industry Median
3.56
Small Cap Median
3.01
P/S RATIO
0.51
Industry Median
3.67
Small Cap Median
2.83
Others
PEG RATIO
-5.70
EV/EBITDA RATIO
18.46
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹84.49 as on Aug 13, 2026.
Growth Score : 4.00The company's growth metrics present a mixed picture. While revenue growth is strong, there are declines in operating profit, earnings per share, asset growth, and net income. This suggests challenges in converting revenue growth into higher profits and efficient asset management. The company needs to address these areas to ensure sustainable growth.
Revenue Growth RateExcellentOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 41.67 | -15.01 | -5.49 | 19.7 | -0.42 |
| Operating Profit Growth Rate | 120 | -27.27 | -50 | -25 | 133.33 |
| Earnings Per Share (EPS) Growth | -7.19 | -42.25 | 12.08 | -14.97 | -1.41 |
| Asset Growth Rate | 5.15 | 18.78 | 4.12 | -3.96 | 2.06 |
| Net Income Growth Rate | 0 | -42.86 | 25 | -20 | 0 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 13.20 | Neutral | 17.00 | 10.65 | 13.00 |
| 2 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 3 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 60.35 | Neutral | 7.00 | 1.40 | 4.00 |
| 4 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 5 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 6 | Quest Laboratories Ltd | 5.27 | 9.34 | Neutral | 18.00 | 9.16 | 15.00 |
| 7 | Sotac Pharmaceuticals Ltd | 5.27 | 17.25 | Neutral | 18.00 | 4.45 | 6.00 |
| 8 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 9 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.36 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
| 10 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
| 11 | PANCHSHEEL | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Aarey Drugs & Pharmaceuticals Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and drug intermediates. It also undertakes contract manufacturing and trading of specialty chemicals. The company serves domestic and international markets, focusing on quality and cost-effective solutions in the pharmaceutical value chain.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Aarey Drugs & Pharmaceuticals Ltd's P/E ratio (TTM) is 60.35, compared to the industry median of 30.38 and large cap median of 28.83.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Aarey Drugs & Pharmaceuticals Ltd's P/B ratio is 1.59, compared to the industry median of 3.56 and large cap median of 3.01.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Aarey Drugs & Pharmaceuticals Ltd's P/S ratio is 0.51, compared to the industry median of 3.67 and large cap median of 2.83.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Aarey Drugs & Pharmaceuticals Ltd's PEG ratio is -5.70.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Aarey Drugs & Pharmaceuticals Ltd's EV/EBITDA ratio is 18.46.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Aarey Drugs & Pharmaceuticals Ltd's ROE is 2.67%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Aarey Drugs & Pharmaceuticals Ltd's ROA is 2.36%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Aarey Drugs & Pharmaceuticals Ltd's ROCE is 6%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Aarey Drugs & Pharmaceuticals Ltd's operating margin is 1.48%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Aarey Drugs & Pharmaceuticals Ltd's net margin is 0.85%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Aarey Drugs & Pharmaceuticals Ltd's current ratio is 1.84.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Aarey Drugs & Pharmaceuticals Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Aarey Drugs & Pharmaceuticals Ltd's interest coverage ratio is 2.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Aarey Drugs & Pharmaceuticals Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Aarey Drugs & Pharmaceuticals Ltd's EPS is -1.41.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹84.49. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1990
Headquarters: Mumbai, Maharashtra
Core Offerings: Active Pharmaceutical Ingredients (APIs), Drug Intermediates, Contract Manufacturing, Trading of Chemicals
Stock Listing: NSE (AAREYDRUGS), BSE (524412)
Promoter: Mundra Group / Suresh Mundra
Aarey Drugs & Pharmaceuticals Ltd was incorporated in 1990 with a focus on manufacturing bulk drugs and drug intermediates. Over the years, the company expanded its product portfolio and manufacturing capabilities. A significant event includes a Rights Issue in 2021 to fund expansion and working capital needs, followed by a stock split in 2023 to improve liquidity and make shares more accessible to retail investors. The company continues to operate in the API and intermediates segment, along with contract manufacturing and chemical trading.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Manufacturing | Approx. 88-90% | Operating Profit |
| Trading of Chemicals & Allied Products | Approx. 10-12% | Operating Profit |
Pharmaceutical Manufacturing: Engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates, catering to various therapeutic areas. The company leverages its manufacturing facilities to produce quality bulk drugs for both domestic and international markets.
Trading of Chemicals & Allied Products: Involved in the trading of various chemicals, complementing its core pharmaceutical business and diversifying revenue streams. This segment includes sourcing and distribution of specialty chemicals.
Mr. Suresh Mundra - Chairman & Managing Director. He is a seasoned professional with extensive experience in the pharmaceutical industry, guiding the company's strategic direction and operational efficiency since its inception.
No major subsidiaries reported.
The company undertook a Rights Issue in 2021 to raise capital for business expansion and working capital. In 2023, it announced a stock split from a face value of Rs. 10 to Rs. 1 per equity share to enhance liquidity.
The Aarey Drugs & Pharmaceuticals Ltd share price today is ₹84.49 on NSE (AAREYDRUGS), as of 26 Sept 2026.
As of 25 Sept 2026, Aarey Drugs & Pharmaceuticals Ltd share price is ₹84.49, with previous close ₹84.49. Today's range is ₹84.49 to ₹84.49. The 52-week range is ₹50.31 to ₹103.99.
As of today, Aarey Drugs & Pharmaceuticals Ltd's market cap is ₹239.95 crore (Small Cap).
Aarey Drugs & Pharmaceuticals Ltd's current P/E ratio is 60.35, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 30.
Aarey Drugs & Pharmaceuticals Ltd's current P/B ratio is 1.59.
Aarey Drugs & Pharmaceuticals Ltd's current dividend yield is N/A. Last dividend of ₹0.10 per share was declared on 22-Sep-2023.
Aarey Drugs & Pharmaceuticals Ltd's EPS (TTM) is ₹-1.41.
Aarey Drugs & Pharmaceuticals Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and drug intermediates. It also undertakes contract manufacturing and trading of specialty chemicals. The company serves domestic and international markets, focusing on quality and cost-effective solutions in the pharmaceutical value chain.
Aarey Drugs & Pharmaceuticals Ltd is promoted by Mundra Group / Suresh Mundra, holding 37.71% as of 25 Sept 2026.
Aarey Drugs & Pharmaceuticals Ltd is listed on NSE (AAREYDRUGS) and BSE (524412). Its next quarterly results are expected on August 2024.
